Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc. (Nasdaq: TPST) is a clinical-stage biotechnology company developing cell therapies and small-molecule drug candidates, primarily for cancer. Its cell therapy portfolio includes autologous, allogeneic and in vivo dual-targeting CAR-T programs, led by TPST-2003 for relapsed or refractory… From the company’s description.
In fiscal 2025, Tempest Therapeutics, Inc. reported a net loss of $26.26M. Operations used $26.82M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tempest Therapeutics, Inc. does
In the company’s own words
Tempest Therapeutics, Inc. (Nasdaq: TPST) is a clinical-stage biotechnology company developing cell therapies and small-molecule drug candidates, primarily for cancer. Its cell therapy portfolio includes autologous, allogeneic and in vivo dual-targeting CAR-T programs, led by TPST-2003 for relapsed or refractory multiple myeloma; other candidates target solid tumors and include programs for renal cell carcinoma and lupus. Its small-molecule candidates are amezalpat, an oral PPARα antagonist studied in combination therapy for first-line hepatocellular carcinoma, and TPST-1495, an oral EP2/EP4 antagonist being advanced for familial adenomatous polyposis. Tempest acquired rights to the CAR-T portfolio in February 2026, adding four programs, including TPST-2003, to its existing drug-candidate pipeline. The company’s development activities include partner-funded studies and an NCI-funded planned Phase 2 study of TPST-1495. Tempest’s business is focused on research and clinical development rather than commercialized products.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BRISBANE, CA
- Fiscal year end
- December
- CIK
- 1544227
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tempest Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tempest Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tempest Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tempest Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tempest Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”